Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Ipsen sells North American rights for Apokyn
December 2011
SHARING OPTIONS:

PARIS—Ipsen has announced the sale of its North American development and marketing rights for Apokyn, indicated in the United States for the acute, intermittent treatment of hypomobility "off" episodes associated with Parkinson's disease, to Britannia Pharmaceuticals. Ipsen acquired the rights along with the U.S. subsidiary of Vernalis PLC in 2008. From Nov. 30 onward, the company will no longer record sales of the drug in its accounts. Britannia Pharmaceuticals will ensure ongoing supply and support of Apokyn to patients through U.S. WorldMeds, a U.S.-based specialty company focusing on neurology, which will take over commercialization of the drug in the United States on Dec. 1. Though no specific financial details were disclosed, the company announced that Britannia Pharmaceuticals will pay more than one time the 2010 sales to Ipsen for the development rights.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.